Pharmather Holdings Ltd · CSE:PHRM
Pharmather — Investor Presentation (October 2026)
26 slides from Pharmather's investor presentation, October 2026
Slide 1: 3D Printing of Personalized Medicine
3D Printing of Personalized Medicine. pharmather.com · m3dicines.com Corporate Presentation · October 2026 CSE: PHRM | OTCQB: PHRRF
Slide 2: Forward-Looking Statements
IM POR TA NT NOT ICE Forward-Looking Statements This presentation contains “forward-looking information” within the meaning of applicable Canadian securities legislation with r espect to PharmaTher Holdings Ltd. (the “Company”). All information other than statements of historical fact is forward-loo
Slide 3: Pharmaceutical 3D printing for personalized medicine
WH O WE AR E Pharmaceutical 3D printing for personalized medicine. PLATFORM M3DICINES Validated formulations · GMP-ready CraftMake printing · Any dose, release or combination Any dose. PI PEL I NE Any release. Proprietary products Any combination — 503A peptides & ketamine · Rare & ultra-rare diseas
Slide 4: Medicine is made for everyone. We make it for one.
OUR M ISSION Medicine is made for everyone. We make it for one. CSE: PHRM | OTCQB: PHRRF
Slide 5: The long tail of dose: medicines mass manufacturing was never built to make
THE OPPOR TU NIT Y The long tail of dose: medicines mass manufacturing was never built to make. Conventional manufacturing only pays at hundreds of thousands of identical units. Personalized peptides Telehealth patients who need a dose made for them Rare and ultra-rare diseases Weight-based doses, o
Slide 6: The exact dose, for the specific patient, on demand — economically
WH Y PHAR M AC EUT ICAL 3 D PR IN TIN G The exact dose, for the specific patient, on demand — economically. Five things mass production can’t do economically — and why each one creates value. Batch size Dose Pill design Process Where it’s made 10 mg 20 mg 40 mg TOD AY Heat Pressure UV Overseas Patie
Slide 7: 3D-printed medicines
OUR PLA TFORM 3D-printed medicines. DIGIT A L RE C IPE 4 · A LR EA D Y P R I NT I NG Patient 10–15 kg band 8 dosage forms · 4 release profiles Dose 250 µg · ±1% Layers A enteric · B IR Format Taste-masked ODT Blend GRAS Geometry Batch Digital, per dose Beads & mini-ta blets Dual-print tablets Gummie
Slide 8: Exclusive North American distributor of CraftMake pharmaceutical 3D printing
COM M ER CIAL F OUN DA TION Exclusive North American distributor of CraftMake pharmaceutical 3D printing. 10,000+ potential placement sites across North America (management estimate). WHA T WE D IS T R IB UT E C US T OM E R S EG ME N T S • CraftMake printers: enclosed, GMP-ready, dual 503A and 503B
Slide 9: Regulation, demand, technology and preparedness are converging
WH Y NOW Regulation, demand, technology and preparedness are converging. US$141B → US$295B US$567B → US$1.2T US$41B → US$59B Peptide therapeutics market, Global personalized-medicine market, Medical countermeasures market, 2025 → 2033 2024 → 2033 2025 → 2030 MEDIC A L REG U LA TIO N IS MO VI NG DEMA
Slide 10: Two pillars. One platform.
BUSIN ESS M ODEL Two pillars. One platform. WE OWN the products and placement infrastructure. WE OPEN the platform to partners. P I L L A R 1 · P RO DU C T P I P E L IN E P I L L A R 2 · P A RT N E RI NG & T EC HN O L O GY Personalized 503A products, including peptides and ketamine Exclusive CraftMa
Slide 11: Five pipeline areas. One printing platform.
P R O D U C T P I P E L IN E Five pipeline areas. One printing platform. Where a precise dose, a combination or a small batch makes a medicine possible. P R O G RA M PA T HW AY S TATUS N E X T M I L ES T O N E 503A personalized products Q4 2026 first launches 503A compounding LA U N CH PL AN N E D N
Slide 12: From injection to a printed oral dose
PR O DUCT SPO TLIGHT · 5 03 A PER SO NA LIZED PR O DUCTS From injection to a printed oral dose. Today’s 503A-eligible peptides are prescribed and compounded through U.S. telehealth platforms, mostly as injections. We print them as chewables, dissolvable tablets and multi-layer combinations, each mad
Slide 13: One ketamine formulation, two markets
PR O DUCT SPO TLIGHT · KE TA MIN E One ketamine formulation, two markets. K E T A M I N E OD T Printed dissolvable tablet Dissolves in the mouth — no water, no needle. Printed size sets the dose; the formulation stays 10 mg 25 mg 50 mg 75 mg 100 mg the same. T E L E HE A L T H 10–100 mg in fine incr
Slide 14: Dose precision is the product
F D A P RO D U CT S PO T LIGH T · R A RE PED IA TR IC D IS E AS E PRO G RA M Dose precision is the product. Children with rare diseases are often dosed from adult tablets cut at home. L E A D F D A - T R AC K PR OG R A M · 5 0 5 ( b ) (1 ) · OR P H A N + P R I O R I T Y R E V I E W VO U C H E R TOD
Slide 15: Approval can earn a priority review voucher — a potential US$100M+ asset
THE PRV OPPORTU N ITY Approval can earn a priority review voucher — a potential US$100M+ asset. WH A T R A R E P E D I A T R I C VO U C H E R S H AV E S OL D FO R ( U S $ M I L L I ON S , R E P OR T E D ) H OW T HE I N CE N T I VE S WOR K $350 Orphan Drug Designation 1 7 years of market exclusivity,
Slide 16: Three underserved markets where small-batch production is an advantage
PIPE LINE EX PAN SION Three underserved markets where small-batch production is an advantage. Each is too small for a production line, and exactly right for pharmaceutical 3D printing. E V A LU AT I N G P LAN N E D E V A LU AT I N G Ultra-rare diseases Psychedelic medicines Discontinued medicines To
Slide 17: Stockpile the inputs, not the pills
M ED I C A L C O UN TE RM EA S UR ES · NA TI O N AL E ME RG EN C Y P RE P AR E D NE S S NO D E NE TW OR K Stockpile the inputs, not the pills. Commercial work in peacetime. Countermeasures in an emergency. Remote areas 1 · Validate Provincial / Digital recipes for priority medicines, held under one
Slide 18: Six business streams that feed each other — and build a moat
COM M ER CIAL PA R TN ER ING Six business streams that feed each other — and build a moat. 1 · P LA C E + 1 NO DE 2 · L IC ENSE 3 · SE LL CraftMake distribution Formulation licensing White-label products Exclusive in North America · 10,000+ potential sites: M3DICINES formulations for personalized do
Slide 19: An asset-light model with three partners, already in place
EX ECU TIO N FO O T PRIN T An asset-light model with three partners, already in place. H A R D WA R E DISP ENSI NG A ND R&D M A N U F A CT U R I N G Exclusive North American distributor Center of Excellence GMP contract manufacturer CraftMake systems, software, materials and PD Labs: a U.S. national
Slide 20: Non-dilutive upside outside the 3D printing core
STRA TEGIC A SSET S Non-dilutive upside outside the 3D printing core. Ketamine ANDA payments expected to begin Q1 2027. Other assets available to license, sell, partner or spin out. Ketamine ANDA KetaVault Ketamine patch KetaMist® Sairiyo Therapeutics FDA-approved ketamine CMC package, INDs, protoco
Slide 21: How our revenue stacks — each layer builds on the last
POTE NT IAL R EV EN UE M ODE L How our revenue stacks — each layer builds on the last. Revenue layers are designed to build on each other — all from the same M3DICINES platform, formulations and data. Approvals add step-change value Priority review voucher sale — potential US$100M+ A rare pediatric
Slide 22: Prove. Build. Lead.
M ILESTON ES Prove. Build. Lead. P RO V E 0–1 2 M ON THS BU I L D 1 2–3 6 M ON THS L EA D BE YO ND First 503A launches Q4 2026; ketamine dissolvable New programs: ultra-rare, psychedelic and Products tablet Q1 2027 discontinued medicines Expanded product and systems portfolio CraftMake orders Q4 202
Slide 23: Our Team
OUR T EAM Leadership across drug development, FDA approvals, commercialization, manufacturing and capital markets. CS Fabio Chianelli Carmelo Marrelli Dr. Beverly J. Incledon Carlo Sansalone Founder, Chairman & CEO Chief Financial Officer Director Director 25+ years in specialty life sciences and Pu
Slide 24: Capital structure
COM PA NY Capital structure As at September 30, 2026 91,019,065 1,500,000 ~19% Issued and outstanding common shares Stock options outstanding Insider ownership PHRM (CSE) PHRRF (OTCQB) COMPANY F ACTS Transfer agent Auditor Fiscal year-end Filings Marrelli Trust Company Limited Truster Zweig Raithath
Slide 25: The opportunity in front of us
S UM M A RY The opportunity in front of us. T H E T AR GE T 1 Large markets and a national US$295B US$1.2T US$59B 10,000+ Peptide therapeutics Personalized medicine Medical countermeasures Potential preparedness nodes network Commercial work in peacetime; by 2033 · up from US$141B by 2033 · up from
Slide 26: Thank You
Thank You info@pharmather.com PharmaTher Holdings Ltd. pharmather.com · m3dicines.com CSE: PHRM | OTCQB: PHRRF
PharmaTher Holdings — Investor Presentation (October 2026) on 6ix